Therapeutic Asset Ratings

146 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Tas-102 Breast Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Cervical Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Chromophobe Renal Cell Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Tas-102 Ciliary Body and Choroid Melanoma, Medium/Large Size	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	P2	CCC (53)
Tas-102 Colorectal Cancer; Lung Cancer	Teclison Ltd.	P2	CCC (53)
Tas-102 Esophageal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Exocrine Pancreas Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Gastric Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Head and Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Hematopoietic and Lymphoid Cell Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Intraocular Melanoma	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	P2	CCC (53)
Tas-102 Iris Melanoma	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	P2	CCC (53)
Tas-102 Lung Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Malignant Neoplasms of Urinary Tract	M.D. Anderson Cancer Center	P2	CCC (53)
Tas-102 Malignant Uterine Corpus Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Malignant Uterine Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 mCRC	Jinan Central Hospital	P2	CCC (53)
Tas-102 Prostate Cancer	John P. Fruehauf	P2	CCC (53)
Tas-102 Prostate Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Recurrent Malignant Solid Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Recurrent Skin Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Recurrent Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions	M.D. Anderson Cancer Center	P2	CCC (53)
Tas-102 Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102 Advanced Microsatellite Stable Colorectal Cancer	Gilead Sciences	P2	CCC (53)

Showing 76 to 100 of 146 assets

PreviousPage 4 of 6Next